Stan Berenshteyn
Stock Analyst at Wells Fargo
(1.07)
# 3,480
Out of 4,820 analysts
54
Total ratings
41.38%
Success rate
-12.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMCL Omnicell | Maintains: Equal-Weight | $40 → $38 | $30.90 | +23.00% | 13 | Apr 17, 2025 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $9 → $8 | $4.61 | +73.54% | 7 | Feb 28, 2025 | |
| HQY HealthEquity | Maintains: Overweight | $110 → $125 | $84.40 | +48.10% | 9 | Feb 26, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $43 → $55 | $56.69 | -2.98% | 10 | Feb 7, 2025 | |
| HCAT Health Catalyst | Maintains: Overweight | $13 → $10 | $4.06 | +146.31% | 5 | Jan 21, 2025 | |
| AMWL American Well | Upgrades: Overweight | $15 | $7.23 | +107.47% | 3 | Jan 13, 2025 | |
| VEEV Veeva Systems | Maintains: Overweight | $275 → $285 | $225.77 | +26.23% | 5 | Dec 6, 2024 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $28 → $23 | $7.16 | +221.23% | 2 | Mar 6, 2023 |
Omnicell
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $40 → $38
Current: $30.90
Upside: +23.00%
GoodRx Holdings
Feb 28, 2025
Maintains: Overweight
Price Target: $9 → $8
Current: $4.61
Upside: +73.54%
HealthEquity
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $84.40
Upside: +48.10%
Doximity
Feb 7, 2025
Maintains: Equal-Weight
Price Target: $43 → $55
Current: $56.69
Upside: -2.98%
Health Catalyst
Jan 21, 2025
Maintains: Overweight
Price Target: $13 → $10
Current: $4.06
Upside: +146.31%
American Well
Jan 13, 2025
Upgrades: Overweight
Price Target: $15
Current: $7.23
Upside: +107.47%
Veeva Systems
Dec 6, 2024
Maintains: Overweight
Price Target: $275 → $285
Current: $225.77
Upside: +26.23%
Teladoc Health
Mar 6, 2023
Maintains: Equal-Weight
Price Target: $28 → $23
Current: $7.16
Upside: +221.23%